Partner, David Selley practises in the fields of corporate and commercial transactions, securities, mergers & acquisitions, corporate finance, banking, competition and regulatory compliance. He has experience in negotiating and drafting corporate documents, including securities offering documents, purchase and sale agreements, loan and security documents, corporate reorganization and restructuring documents, and other contracts. David acts for clients in a variety of industries, including technology and information communications, natural resources, financial services, and industrial businesses. He represents large, publicly-traded companies, venture companies, private companies, and early stage companies and provides both strategic advice with respect to corporate transactions and ongoing general corporate advice. David also heads the corporate services department. He was named by Lexpert®, Canada’s most respected legal publication, as one of Canada’s leading lawyers under 40. This award honours rising stars in the legal community under the age of 40 as selected by Lexpert’s Advisory Board. He is also named in The 2021 Best Lawyers in Canada directory. BV rated by Martindale-Hubbell. Admitted to the British Columbia Bar (1998).
On May 21, 2019, Diversified Royalty Corp. completed its royalty transaction with Mr. Mikes Restaurants Corporation .As part of the transaction, DIV indirectly acquired the trademarks and other intellectual property rights utilized by Mr. Mikes in its business
Diversified Royalty Corp. completed its royalty transaction with Nurse Next Door Professional Homecare Services Inc. to indirectly acquire the trademarks and certain intellectual property rights utilized by Nurse Next Door in its premium home care business
On November 27, 2016, Cara Operations Limited (“Cara”), Canada’s oldest and largest full-service restaurant company, completed its acquisition of a majority ownership interest in Original Joe’s Franchise Group Inc. (“Original Joe’s”) for $93 million.
Tekmira Pharmaceuticals Corporation (“Tekmira”) completed a merger of equals with OnCore Biopharma, Inc. (“OnCore”) whereby OnCore merged with a wholly-owned subsidiary of Tekmira. As a result of the merger, stockholders of OnCore hold approximately fifty per cent (50%) of the total number of outstanding shares of capital stock of Tekmira. The implied market value of the combined company, based on the closing price of Tekmira common shares on the NASDAQ Global Market on January 9, 2015, was approximately USD$750 million and at time of closing USD$964 million.